

Antimicrobial therapy

Prof Ivo Ivić

Bacterial sensitivity to specific antibiotic


Determinants

- ✿ MIC- minimal inhibitory concentration
 - ◆ disables visible bacterial growth in liquid media (12h)
 - ◆ allows growth after inoculation on solid media


- ✿ MBC- minimal bactericidal concentrations
 - ◆ kills all bacteria
 - ◆ no growth after inoculation on solid media

Principles of treatment

A



B




Requirements for treatment success

(using conventional dosage of antibiotic)

- ◆ to achieve serum antibiotic concentrations above MIC
- ◆ to maintain this concentrations for enough long period after administration

The lower the MIC,
the better the therapy

The greater the AUC,
the better the therapy



Bacterial sensitivity to specific antibiotic – antibiogram

❖ Sensitive

- ◆ low MIC values for specific antibiotic
- ◆ conventional dosage = high probability of cure

❖ Resistant

- ◆ high MIC values for specific antibiotic
- ◆ therapeutic concentrations not achievable by conventional or increased dosage


Bacterial sensitivity to specific antibiotic – antibiogram

✳ Intermediate sensitivity

- ◆ MIC values increased (but not high)
- ◆ possibility of treatment failure
- ◆ Increased dosage = sometimes provides therapeutic success

Example

Str.pneumoniae intermediately penicillin sensitive



Recovery from bacterial infection: relationship between antibiotic and neutrophils

❖ Antibiotic:


- ◆ reduces number of bacteria
- ◆ facilitate clearing of bacteria by neutrophils

❖ At level of 10^2 - 10^3 bacteria/g of tissue

- ◆ Neutrophil clean bacteria without help of antibiotic
- ◆ Usually, this is achieved after 5 days of therapy



MAKING DECISION FOR ANTIBOTIC THERAPY





Making decision for antibiotic therapy: Checklist

1. Assess the possibility of bacterial infection
2. Assess site of infection/pathogen(s) involved
3. Assess antibiotic susceptibility of presumed pathogen
4. Check data about previous antibiotic therapy/resistance
5. Check important predisposing host factors
6. After 3 days select drug with the narrowest antibacterial spectrum


Rational selection of antibiotics

Questions to be answered


1. How broad is antibacterial spectrum of chosen antibiotic?
2. Whether the antibiotic(s) is -cidal or -static?
3. What are the antibiotics major toxicities?
4. How is the drug metabolised and eliminated? Is there need for dosing adjustment?
5. What is the price of the antibiotic selected?

Antibacterial spectrum of some antibiotic groups

Group	Narrow spectrum	Moderately broad	Broad	Very broad
Penicillins	Penicilin G/V	Amoksicillin	Amoksicillin - calvulanate	Ticarcillin-clavulanate
Cephalosporins	Cefalexine	Cefuroksime - aksetil	Ceftriaxone	Cefepime
Fluoroquinolones		Cipofloxacin	Levofloxacin	Moksifloxacin
Glycopeptides	Vancomycin			
Macrolides		Azithromycin		
Tetracyclines			Doxycycline	
Carbapenems				Impenem Meropenem




ANTIBIOTICS



Antibiotic groups:


1. β -lactams
2. Aminoglycosides
3. Glycopeptides
4. Macrolides
5. Ketolides
6. Lincosamides
7. Tetracyclines
8. Chloramphaenicol
9. Quinolones
10. Oxazolidines
11. Streptogramins
12. Daptomycin
13. Metronidazol
14. Sulfonamides
15. Trimetoprim
16. Colistin

β -LACTAM ANTIBIOTICS




R_1 side chain:

-anibacterial properties



Penicillins

β -Lactam Antibiotics




Cephalosporins

R_2 side chain:

-pharmacokinetics
-metabolism




The family tree of β -lactam antibiotics




Antibacterial mechanism of β -lactams

★ Inactivation of cell wall enzymes (PBP-s)



★ Cessation of cell wall synthesis

- ◆ during active cell growth and division



★ Cell lysis = bactericidal effect

- ◆ antagonised by bacteriostatic agents

Bacterial resistance mechanisms

- ★ Destruction of β -lactam ring by β -lactamases

- ◆ penicillinases, cephalosporinases, carbapenemases

- ★ Modification of PBP-s

- ◆ lowered affinity for specific β -lactam antibiotic
 - ◆ preserved cell wall synthesis

Hipersensitivity to β -lactam antibiotics

❖ The most common toxicity

❖ Immediate or Delayed



◆ Anaphylactic (IgE mediated)

- Urticaria, angioedema Quincke
- Asthmatic attack
- Anaphylactic shock



◆ Non-anaphylactic

- Maculopapular rash

Hipersensitivity: Penicillins vs Cephaloporins

★ Penicillins

- ◆ 1-10 % allergic reactions
- ◆ 1-7% cross-reactity to cephalosporins

★ Cephalosporins

- ◆ 1- 3% allergic reactions
- ◆ rarely anaphylactic

A practical approach in case of penicillin allergy

★ Anaphylactic

- ◆ all β -lactams should be avoided
- ◆ or desensitization should be carried out

★ Non-anaphylactic


- ◆ another group of β -lactams is allowed

Other β -lactam adverse reactions

- ★ Imipenem: seizures
 - ◆ in patients with renal dysfunction
 - ◆ less frequent with other carbapenems
- ★ Ceftriaxon: aseptic inflammation of gallbladder
 - ◆ drug crystalisation in gallbladder
- ★ Cephalosporins + aminoglycosides: nephrotoxicity
- ★ *Clostridium difficile* diarrhoea



PENICILLINS



Penicillins

1. Natural penicilins
2. Aminopenicilins
3. Penicillinase-resistant pencillins
(anti-staphylococcal)
4. Carboxypencillins and ureidopencillins
(anti-pseudomonal)

1.Natural penicilins (PCN)

❖ Narrow spectrum

- *S.pygenes, S. viridans, S.pneumoniae, Neisseria meningitidis*
- Anaerobic mouth flora
- *Clostridium perfrigens, C.tetani, Leptospira*

❖ Short half-life: dosage 3-6 times/day

❖ Renal excretion: dose adjustment with renal function

Preparations

- ◆ i.v. : PCN G
- ◆ i.m.: procaina PCN G, benzathine PCN G
- ◆ p.o.: PCN V-K

2. Aminopenicillins (iv, im, po)

2a. Amoxycillin , Ampicillin

❖ Moderate spectrum:

- ◆ Gram-positive: *Streptococci.*, *Enterococci*, *Lysteria*
- ◆ Gram-negative: *E.coli*, *Salmonella*, *Haemophilus influenzae* (if β -lactamase sensitive)

❖ Short half life

❖ Renal excretion (unchanged)

2b. Amoxycillin-clavulanate , Ampicilin-sulbactame

- ❖ Broader spectrum with addition of:
 - ◆ Meticillin sensitive *Staphylococcus aureus* (MSSA)
 - ◆ β -lactamase producing gram-negative bacteria:
 - *Moraxella catarrhalis*,
 - *H.influenzae*,
 - *Enterobacteriaceae*.

3. Penicillase-resistant penicillins (iv, po) (methicillin sensitive bacteria)

Methicillin, Cloxacillin, Dicloxacillin

- ❖ Very narrow spectrum-
 - ◆ Indication: *MSSA*, *S.pyogenes* (cellulitis)
 - ◆ Ineffective against anaerobes and gram-negative bacteria
- ❖ Short half-life
- ❖ Hepatobiliary elimination (bile excretion)

- ❖ Rezistant to β -lactamase produced by gram-negative bacteria:
 - ◆ Pseudomonas, other enterobacteriaceae

Nowdays market- only with β -lactamase inhibitors:

- ❖ Tikarcilin-clavulanate
 - ❖ Piperacilin-tazobactam

Activity against:


- Gram-negative bacteria
 - Anaerobes (+ *B.fragilis*)
 - MSSA

Intrabdominal infections

VAP

Mixed soft tissue infections

VAP- ventilator associated pneumonia



CEPHALOSPORINS

	Antibacterial activity of cephalosporins			
	<u>1st generation</u>	2nd generation	3rd generation	4th generation
Gram + cocci	+++	++	++	++
Gram neg. bacilli	+	++	+++	+++
MSSA	++	+	+/-	++
MRSA	-	-	-	-
	Cephalexin Cefazolin	Cefuroxime Cefoxitine Cefuroxim- axetil	Ceftriaxone Cefotaksim Ceftazidim Cefixime	Cefepime

1st generation cephalosporins

❖ Activity:

- ◆ Streptocci, MSSA, oral cavity anaerobes
- ◆ CA gram-negative bacilli (*E.coli*)

❖ Ineffective against

- ◆ MRSA, penicillin-resistant *S.pneumoniae*
- ◆ *H.influenzae*

❖ Renal excretion

❖ Do not pass blood-brain barrier

❖ Good for soft tissue infections

2nd generation cephalosporins

- ❖ Similar to 1st generation, wider gram neg.activity
 - ◆ *H.influenzae, Neisseria sp, Moraxella catarrhalis*
- ❖ Renal excretion
- ❖ Indications
 - ◆ Uncomplicated UTI, otitis media
 - ◆ Soft tissue infection, pelvic inflammatory disease
- ❖ Oral preparation (cefuroxim-axetil):
 - ◆ low serum levels
 - ◆ expensive

3rd generation cephalosporins

Activity

- ◆ Excellent against gram negative bacteria
 - *Neisseria sp, H.influenzae, M.catarrhalis*
 - *Enterobacteriaceae*
 - Ceftazidime: the only active against *Ps.aeruginosa*
- ◆ Excellent against gram positive cocci
 - *S.pyogenes, S.viridans*, other streptococci
 - *S.pneumoniae* (including moderately PCN resistant strains)
- ◆ **Poor** against *S.aureus* and highly PCN resistant *S.pneumoniae*

3rd generation cephalosporins

❖ Ceftriaxon- long half life: 1-2 doses/day

- ◆ Other 3.gen.: 3-4 doses/day

❖ All cross blood brain barrier

❖ Excretion

- ◆ Renal: for most members
- ◆ Ceftriaxone: hepatal (gallbladder crystals!)

❖ Indications:

- ◆ CA pneumonia and meningitis
- ◆ UTI and abdominal infections

CA: Community Acquired

3rd generation cephalosporins

PARENTERAL (iv, im)

- ❖ Cefotaxime
- ❖ Ceftriaxone
- ❖ Ceftazidime

ORAL

- ❖ Cefexime
- ❖ Cefpodoxime proxetil

4th generation cephalosporins (cefexime)

- ❖ Resistant to ESBL
- ❖ Wide antibacterial spectrum
 - ◆ Similar to 3rd gen.cephalosporins
 - plus: *Ps.aeruginosa* and MSSA (but not MRSA!)

Indications

- ❖ Nosocomial infections (iv)

ESBL: Extended Spectrum Beta Lactamase


5th generation cephalosporins (ceftaroline)

❖ Antibacterial spectrum


- ◆ Similar to 3.gen.cephalosprins(ceftriaxon)
plus: MRSA and VISA (vancomycin intermediately resistant SA)

❖ Indications

- ◆ CA pneumonia
- ◆ Complicated soft tissue infections



CARBAPENEMS



Carbapenems

Very wide antibacterial spectrum

★ Gram negative bacteria, including:

- ◆ ESBL producing strains
- ◆ *P.aeruginosa* (with exception of ertapenem)

★ Gram positive bacteria, including:

- ◆ MSSA (but not MRSA)

★ Anaerobes

Carbapenems

❖ Indications (pending results of the microbiology)

- ◆ Severely ill patients with nosocomial infection
- ◆ Severe mixed infections

Carbapenem members

1. Imipenem-cilastatin
2. Etrapenem (1 dose/day, inactive against *P.aeruginosa*)
3. Meropenem
4. Doripenem



AMINOGLYCOSIDES

Aminoglycosides

- ❖ Derived form *Streptomyces* bacteria
- ❖ Bactericidal, but inactive low pH medium
- ❖ Post-antibiotic effect:
 - ◆ Short exposure to antibiotic
 - ◆ Prolonged suspension of bacterial growth
(despite falling of antibiotic level below MIC)
 - ◆ The higher dose, the longer post-antibiotic effect
 - ◆ 1 dose/day is possible

Aminoglycosides

Activity

- ❖ Excellent against gram-negative bacteria
- ❖ Synergy with penicillins for:
 - ◆ *S.viridans, Enterococcus, P.aeruginosa*
 - But not as monotherapy for them
- ❖ Renal excretion
 - ◆ deceased creatinin clearance → dose adjustment

Aminoglycosides

Toxicity

- ✿ Nephrotoxicity (usually reversible)
- ✿ Ototoxicity (usually irreversible)
- ✿ Avoid aminoglycosides in:
 - ◆ Eldery patients
 - ◆ Renal disease
 - ◆ Patients with liver disease
 - ◆ Dehidration and hypotension
 - ◆ Combination with cephalosporins, vankomycin, clindamycin, furosemid
- ✿ Monitoring of serum levels is recommended

Aminoglycosides (iv, im)

- ◆ Gentamicin
- ◆ Amikacin
- ◆ Netilmicin

- ◆ Tobramycin (topical th- eye infections)
- ◆ Streptomycin (tularemia, plague)



GLYCOPEPTIDES

Vancomycin

Teicoplanin

Glycopeptides

- ★ Inhibit cell wall synthesis (peptidoglycan)- bactericidal
 - ◆ Long half life, postantibiotic effect
 - ◆ 1-2 dose/day
 - ◆ Unreliable passage through blood-brain barrier
- ★ Activity
 - ◆ Gram positive cocci
 - ◆ SA, *S.pneumoniae*, *Enterococcus*, etc.
- ★ Renal excretion
 - ◆ Decreased creatinin clearance ➡ Dose adjustment

Glycopeptides


Toxycity

- ❖ “Red man syndrome” – rapid drug infusion
 - ◆ Redness of face and torax
 - ◆ Not thtrue allergic reaction
 - ◆ Rapid infusin- local hiperosmolarity- release of histamine
 - ◆ infusion should be slow (1h)

- ❖ Rare ototoxicity *and* nephrotoxycity


Limited therapeutic indications

1. MR staphylococci (MRSA and koagulasa neg.)
2. PCN highly resistant *S.pneumoniae*
3. Enterocci in patients with PNC allergy
4. *Clostridium difficile* diarrhoea iresponsible to metronidazol (oral therapy)



MACROLIDES AND KETOLIDES

Macrolides and Ketolides



Activ against macrolide
resistant bacteria

Macrocyclic lactone ring- basic component

Macrolides

- Erytromycin (natural antibiotic)
- Azitromycin (iv, po)
- Clarithromycin (po)

Ketolides

- Telithromycin (po)

One site of action

Two sites of action

Mode of action:
Inhibition of protein synthesis

Toxicity (rare, safe groups)

Macrolides


- ✿ Gastrointestinal
 - ◆ nausea, vomiting, cramps, diarrhoea
 - ◆ most often erithromycin

- ✿ Prologed QT-interval

Ketolides

- ✿ Disturbed accomodation
 - ◆ blured vison
- ✿ Severe hepatitis
 - ◆ very rare

Both metabolised
by cytochrome P450



Increase levels of:

- Shrot acting benzodiazepines
- Ritoanvir
- Tacrolimus, ect.

Pharmacokinetics

- ❖ Long half life (except eritromycin): 1-2 doses/day
 - ◆ Azithromycin: prolonged activity (5 days after cessation)
- ❖ Elimination by bile
 - ◆ Azithromycin unchanged
- ❖ High tissue concentrations of drugs
 - ◆ 10-100 times of serum conc.
- ❖ Unsuitable to treat bacteriema/sepsis
- ❖ Do not cross blood brain barrier

Anitbacterial spectrum

Vide:

- ❖ Gram-positive and –negative bacteria,
- ❖ Oral anaerobes
- ❖ Intracellular bacteria
- ❖ Mycoplasma, Ureplasma, Chlamidia, Legionella
- ❖ Atypical mycobacteria

Treatment indications

- ❖ Community acquired pneumonia
 - ◆ *S.pneumoniae*- increasing resistance
 - ◆ Atypical pneumonia- drugs of choice

- ❖ *S.pyogenes*
 - ◆ increasing resistance
 - ◆ reserve for PCN allergy

Treatment indications (continued)

- ❖ Atypical pneumonia
- ❖ Legionnaire disease
- ❖ STD (myoplasma, ureaplasma, chlamida)
- ❖ Atypical mycobacteria

- ❖ Replacement of penicillin in case of allergy

STD: Sexually Transmited Diseases




CLINDAMYCIN (PO, IV)

Clindamycin

Mechanism

- ◆ Inhibits bacterial protein synthesis
 - the same site of action used by macrolides

★ Excretion: liver → bile → stool



★ Toxicity

- ◆ Diarrhoea

- reduction of sensitive flora up to 14 posttherapy days
- *Cl. difficile* is involved in 50%

Antibacterial spectrum

- ❖ MSSA, *S.pneumonae*, *S.pyogenes*

- ◆ for PNC-allergic patients

- ❖ Anaerobic bacteria

- ◆ rising resistance of *B.fragilis* !!

- ❖ Toxoplasma gondii

- ◆ for sulfa-allergic patients

Poor or no activity against gram-negative bacteria

TETRACYCLINES

Doxycycline (po)

Tigecycline (po, iv)

Tetracycline

Mechanism

- ◆ Inhibition bacterial protein synthesis

★ Excretion: liver → bile → stool

★ Toxycity

- ◆ Photosensitivity- rash
- ◆ Deposition in enamel- teeth discoloration
 - not recommended under age of 8 years
- ◆ Benign intracranial hypertension (headache)

Tetracycline

Other antibiotics are better !

Antibacterial spectrum

Very wide:

- ❖ gram positive and gram negative bacteria
- ❖ Anaerobic bacteria

❖ Intracellular bacteria


- ◆ *Mycoplasma, Ureaplasma*
- ◆ *Chlamida*
- ◆ *Ricketssia*
- ◆ *Borellia*
- ◆ *Brucella*

} primary indication

Tigecycline- the new member

Improved activity against resistant :

- ❖ gram positive bacteria
- ❖ gram-negative bacteria
 - ◆ but not *Pseudomonas* and *Proteus* !!
- ❖ Limited indication
 - ◆ use as reserve antibiotic
 - multiresistant nosocomial infections



— · — · — · — · — · — · — · — · — · — · —

CHLORAMPHENICOL

Chloramphenicol

- ❖ Wide spectrum, bactericidal for:
 - ◆ *S.pneumoniae, H.influenzae, N.meningitidis*

- ❖ Excellent body distribution
 - ◆ CSF conc. = 50% serum conc.

Toxicity

- ❖ Aplastic anemia
 - ◆ Reason for stopping of production (justified???)



QUINOLONES

(or fluoroquinolones)

1. Ciprofloxacin
2. Gatifloxacin
3. Levofloxacin
4. Gemifloxacin
5. Moxifloxacin



Quinolones = two 6-member rings

-
- ❖ **Fluorine** addition: = enhanced antibacterial activity
 - ❖ **Piperazin** addition = enhanced gram-negative activity

Mechanism: inhibition of bacterial DNA- 2 points

1. formation of helix (DNA coiling)
2. division of DNA

Excretion:

- ◆ Kidneys: ciprofloxacin, levofloxacin, gatifloxacin
- ◆ Liver: gemifloxacin, moxifloxacin

Toxicity

- ❖ Tendinitis
- ❖ Articular cartilage damage
 - ◆ quinolones are not recommended in children
- ❖ A-V blok (prolonoged QT interval)

Ciprofloxacin : antibacterial spectrum

❖ Gram negative (wide)

- ◆ Primarily for *Pseudomonas*
- ◆ Other gram negative bacteria
 - as alternative drug
 - for prostatitis (high concentrations)

❖ Intracellular bacteria

- ◆ *Chlamidia, Mycoplasma, Ureaplasma*
 - in case of prostatitis

❖ Gram positive (narrow)

- ◆ MSSA- bone infections


Respiratory quinolones): antibacterial spectrum (levo-, gati-, gemi-, moxi-floxacin)

Ciprofloxacin spectrum, plus:

- ◆ *S.pneumoniae* (even PCN resistant)
- ◆ Anaerobic bacteria (gemifloxacin)


★ Indications of respiratory quinolones:

- ◆ CAP (community acquired pneumonia)
- ◆ Mixed infections of soft tissue



OXAZOLIDINES

linezolid



linezolid

- ❖ Inhibits protein synthesis
- ❖ Oral and parenteral preparations
 - ◆ wide body distribution, high CSF concentrations
- ❖ Excretion: metabolised in urine
- ❖ Toxicity: reversible thrombocytopenia (>2 weeks th)


linezolid

Antibacterial spectrum

- ❖ Spectrum: only gram positive bacteria
 - ◆ Vancomycin resistant Enterococcus (VRE)
 - major indication
 - ◆ MRSA- as alternative drug
 - ◆ PCN resistant *S.pneumoniae*- alternative drug



METRONIDAZOL



metronidazol

- ❖ Damage of bacterial DNA
 - ❖ Oral and parenteral preparations
 - ◆ Wide body distribution, good CSF penetration
 - ❖ Excretion by the liver
- Toxicity:
- ◆ Disulfiram reaction with alcohol consumption
 - ◆ Should be avoided in pregnancy (DNA damage ??)


Antibacterial spectrum and indications

★ Anaerobic bacteria

- ◆ major indication
- ◆ usually with cephalosporins (mixed infections)

★ *Clostridium difficile* diarrhoea

★ Genital *Trichomonas vaginalis*



TRIMETROPRIM +

SULPHAMETOXASOLE

(TMP+SMX, Cotrimoxasole)

trimeproprim : sulphametoxasol = 1:5

- ❖ Sinergistic inhibiton of DNA precursors synthesis
- ❖ Oral and parenteral preparations
- ❖ Excretion by urine
- ❖ Toxicity:
 - ◆ Photosensitive skin rash
 - ◆ Erythema multiformae and Steven-Johnson's sy.
 - ◆ Serum sickness-like disease
 - ◆ Hemolytic anemia (in G6P deficiency)

Antibacterial spectrum and indications

- ❖ Wide G+ and G- spectrum
- ❖ Growing resistance
 - ◆ Previously- first choice drug for uncomplicated UTI
 - ◆ Nowdays – second choice drug (according to antibiogram)
- ❖ First choice for:
 - ◆ *Nocardia asteroides*
 - ◆ *Pneumocystis jirovecii* } Immunocompromised hosts
(HIV, immunosuppressive th)

OUTPATIENT ORAL ANTIBIOTICS

Reccommendations

When?

- ★ higly suspected or proven bacterial infection

Whom to?

- ★ mild to moderately ill patients

Which antibiotic?

- ★ accoridng to reccommendations

- ◆ IDSA- Infectious Disease Society of America
- ◆ ESCMID- European Society of Clinical Microbiology and Infectious Disease
- ◆ CDC- Center for Disease prevention and Control (USA)
- ◆ ECDC- European CDC


For instance

- ✿ Bacterial (streptococcal) pharyngitis

- ◆ first choice: Penicillin VK
- ◆ PCN allergy: Azithromycin

- ✿ Community acquired pneumonia (CAP)

- ◆ first choice: amoxicillin or doxycycline
- ◆ comorbidity: levo- or moxifloxacin



ANTIFUNGAL AGENTS

Antifungal agents

Polienes

- ❖ Amphotericin B

Azoles

- ❖ Fluconazole
- ❖ Ketoconazole
- ❖ Itraconazole
- ❖ Posaconazole
- ❖ Voriconazole

Echinocandins

- ❖ Caspofungin
- ❖ Anidulafungin
- ❖ Micafungin

Others

- ❖ Flucytosine
- ❖ ect.....

Modes of action of antifungals

1. Polyenes

- ◆ ergosterol binding = disrupted membrane synthesis
- ◆ fungicidal

2. Azoles

- ◆ inhibition of ergosterol synthesis pathway
- ◆ fungistatic

3. Echinocandins


- ◆ Blocking of cell wall synthesis (β -glucan)

4. Flucytosine


- ◆ Impairment of DNA and RNA synthesis

Modes of action of antifungals

Amphotericin B



Echinocandins





AMPHOTERICIN B (AB)

Toxicity

- ★ Nephrotoxicity- usually reversible
 - ◆ Reduced by hydration
- ★ Fever during infusion, reduced by:
 - ◆ Slow infusion (few hours)
 - ◆ Corticosterid premedication
- ★ Phlebitis
 - ◆ Usually CVC required

Preparations of AB


All intravenous, same antifungal spectrum, but:

1. ABD- amphotericin B deoxycholate
 - ◆ The most nephrotoxic. The cheapest.
2. Lipid-complex AB
 - ◆ Less nephrotoxic. More expensive.
3. Liposomal AB
 - ◆ Almost non-nephrotoxic. Extremely expensive.


Antifungal spectrum and indications

Systemic infections (but not CNS):

- ◆ most *Candida*
- ◆ *Aspergilus*
- ◆ *Cryptococcus*
- ◆ *Histoplasma*
- ◆ *Blastomyces*
- ◆ *Coccidiomycес*
- ◆ *Zygomycес*



AZOLES



Toxicity

★ Generally minimal

- ◆ gastrointestinal complaints
- ◆ reversible liver enzymes elevation

★ Ketoconazole

- ◆ reduced libido
- ◆ severe hepatitis

★ Voriconazole

- ◆ transient loss of vision during the first few infusions

Antifungal spectrum and indications

Systemic (including CNS) infections
and extensive local infections (iv, po)

★ Posaconazole and Voriconazole

- ◆ wide spectrum, the same as AB
 - very expensive

★ Flukonazole, Itraconazole

- ◆ Inactive against *Aspergilus*



ANTIVIRALS (OTHER THAN ANTI-HIV AGENTS)

Ribavirin

Interferon- α

Neuraminidase inhibitors

RIBAVIRIN

Mechanism of action

- ◆ Interference with m-RNA
- ◆ Not clearly understood

Toxicity

- ◆ Oral- reversible hemolytic anemia
- ◆ Aerosol- bronchospasm

Pharmacokinetics

- ◆ Excretion by the liver and kidney

Indications

- ★ RSV bronchiolitis
- ★ Lassa hemorrhagic fever (Lassa virus, Arenaviridae)
- ★ Chronic hepatitis C
 - ◆ only combined with interferon- α

INTERFERON- α (INF- α)

❖ Natural occurring antiviral cytokines

Mechanism of action

- ◆ enhances immunological killing of virus-infected cells
- ◆ poor activity against DNA viruses

❖ Pharmacokinetics (sc, im)

- ◆ long half-life: 2-3 doses/week
- ◆ Pegliated form (PegINF- α): 1 dose/week

INTERFERONS

Toxicity

❖ Fever

❖ Irritability, depression, somnolece

❖ Bone marrow supression

- ◆ neutropenia, thrombocytopenia

Indications

- ❖ Chronic hepatitis C
 - ◆ Combined with ribavirin
- ❖ Chronic hepatitis B
- ❖ Kaposi sarcoma (HHV-8)
- ❖ Condyloma acuminatum (HPV)

NEURAMINIDAZE INHIBITORS

(oseltamivir, zanamivir)

Mechanism of action

- ◆ inhibit enzim important for budding:
 - release of influenza virus from infected cell
- ◆ effective within first 48h of disease

Toxicity

- ◆ Zanamivir (aerosol)- bronchospasm
- ◆ Oseltamivir (po)- safe

Indications

- ❖ Complicated influenza A and B
 - ◆ with pneumonia

- ❖ Influenza in high risk patients
 - ◆ Therapy of uncomplicated influenza
 - ◆ Prolonged prophylaxis (half doze)